Deac Andrada-Larisa, Burz Claudia Cristina, Bocşe Horea Florin, Bocşan Ioana Corina, Buzoianu Anca-Dana
"Prof. Dr. Ion Chiricuţă" Oncology Institute, Cluj-Napoca, Romania.
Immunology and Allergology, Department 2 - Functional Sciences, Faculty of Medicine, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania.
Med Pharm Rep. 2020 Jul;93(3):223-230. doi: 10.15386/mpr-1564. Epub 2020 Jul 22.
Fluoropyrimidines, after more than 50 years from their discovery, are still the treatment of many types of cancer, and it is estimated that two million patients receive fluoropyrimidine therapy annually. The toxicity associated with fluoropyrimidines affects 30-40% of patients and some adverse effects can be lethal. Dihydroypyrimidine dehydrogenase is the main enzyme in the catabolism of 5-FU and DPD activity deficiency can cause important toxicity. This is an important reason to determine DPD activity in order to improve patient safety and to limit potential life-threating toxicity. At presentmultiple phenotypic and genotypic methods are available for the determination of DPD activity, some of these methods have proven their usefulness in practice, and yet they are not routinely recommended in clinical practice. This review is another statement of the importance of the determination of DPD status, the phenotypic and genotypic methods that are available and can be used.
自氟嘧啶被发现50多年来，它们仍然是多种癌症的治疗药物，据估计每年有200万患者接受氟嘧啶治疗。与氟嘧啶相关的毒性影响30%至40%的患者，一些不良反应可能是致命的。二氢嘧啶脱氢酶是5-氟尿嘧啶分解代谢的主要酶，二氢嘧啶脱氢酶活性缺乏可导致严重毒性。这是测定二氢嘧啶脱氢酶活性以提高患者安全性并限制潜在致命毒性的一个重要原因。目前有多种表型和基因型方法可用于测定二氢嘧啶脱氢酶活性，其中一些方法已在实践中证明了其有用性，但在临床实践中它们并未被常规推荐。本综述再次强调了测定二氢嘧啶脱氢酶状态的重要性，以及现有的和可使用的表型和基因型方法。
